GLP-1 Medication vs Bariatric Surgery

Weight loss injections and bariatric (weight loss) surgery are both treatments for obesity, but they work in different ways and suit different people. On average, surgery such as gastric bypass or sleeve gastrectomy produces larger and longer-lasting weight loss, backed by decades of follow-up. Newer GLP-1 medicines, particularly tirzepatide (Mounjaro), have narrowed the gap in trials, avoid an operation and can be stopped, but weight often returns when they are. There is no single right answer. The choice depends on your BMI, health, preferences and risk, and should be made with a GP and specialist team.

Two different approaches to the same condition

Obesity is now widely recognised as a chronic, relapsing condition shaped by biology, environment and genetics, rather than a simple matter of willpower. Our guide to obesity as a chronic disease explores this. Both surgery and GLP-1 medicines work partly by changing the body's appetite signals, which is why they tend to be more effective than diet and exercise alone for people with severe obesity.

How GLP-1 medicines work

GLP-1 medicines mimic, or act on the receptors for, hormones released by the gut after eating. They reduce appetite, increase the feeling of fullness and slow stomach emptying. In the UK, the licensed injections for weight management are:

• Mounjaro (tirzepatide), a weekly injection that acts on both GLP-1 and GIP receptors
• Wegovy (semaglutide), a weekly GLP-1 injection
• Saxenda (liraglutide), a daily GLP-1 injection

At the time of writing, two GLP-1 tablets have also been authorised by the MHRA for weight management: the Wegovy tablet (oral semaglutide) and Foundayo (orforglipron). Our overview of weight loss injections and our guide to every UK weight loss injection compared explain the differences.

These medicines work only while you take them. Their effect on appetite fades within weeks of stopping.

How bariatric surgery works

Bariatric surgery physically changes the stomach and sometimes the small intestine. The main operations offered in the UK are:

• Sleeve gastrectomy: around three-quarters of the stomach is removed, leaving a narrow tube or "sleeve". This reduces how much you can eat and changes gut hormone signals.
• Gastric bypass (Roux-en-Y): the stomach is divided to create a small pouch, which is connected directly to a lower part of the small intestine, bypassing the rest of the stomach and the first part of the intestine.
• Gastric band: an adjustable band is placed around the top of the stomach. Bands are now used less often in the UK than sleeve and bypass operations, partly because of higher rates of long-term problems and re-operation.

Surgery is not simply about restriction. Bypass and sleeve operations change the release of gut hormones, including GLP-1 itself, which is one reason they reduce hunger so markedly. In a sense, GLP-1 medicines reproduce part of what surgery does to the body's hormonal signalling, but without changing anatomy.

How the results compare

Weight loss with GLP-1 medicines

The headline trials for licensed GLP-1 medicines reported the following average results:

These figures are averages. Some people lose much more, and some respond very little. Weight loss typically levels off after about a year while treatment continues.

Weight loss with surgery

Weight loss after surgery is often reported in different ways, which makes direct comparison tricky. In broad terms, people having sleeve gastrectomy or gastric bypass commonly lose around a quarter to a third of their body weight in the first one to two years, with some regain over the following years. Gastric bands generally produce less weight loss.

The longest-running evidence comes from the Swedish Obese Subjects (SOS) study, published in the New England Journal of Medicine in 2007 and followed up since. It compared people who had surgery with matched people receiving usual care. Weight loss was sustained over many years in the surgical group, and surgery was associated with lower overall mortality over long-term follow-up. Because SOS was not a randomised trial and used older operations, its results need careful interpretation, but it remains one of the most important long-term datasets in obesity care.

Diabetes and other conditions

Both approaches can improve weight-related health conditions. The STAMPEDE trial, which compared bariatric surgery with intensive medical therapy in people with type 2 diabetes, found that surgery led to better blood sugar control over five years, and many participants were able to reduce or stop diabetes medicines. It is important to note that STAMPEDE's medical arm did not include modern GLP-1 medicines at the doses now used for obesity.

For GLP-1 medicines, the SELECT trial showed that semaglutide 2.4mg reduced major cardiovascular events by about 20% in people with established cardiovascular disease and overweight or obesity. Tirzepatide has shown benefits in obstructive sleep apnoea and in blood sugar control. See our guides to tirzepatide and sleep apnoea and GLP-1s and type 2 diabetes.

Side-by-side comparison

Risks in more detail

Risks of GLP-1 medicines

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, indigestion and reflux. They are usually worst when starting treatment or increasing the dose and often ease over weeks. Rarer but more serious risks listed in the SmPCs include:

• acute pancreatitis
• gallstones and gallbladder inflammation, partly linked to rapid weight loss
• dehydration and kidney problems from persistent vomiting or diarrhoea
• worsening of diabetic eye disease in people with diabetes whose blood sugar improves rapidly
• low blood sugar when combined with insulin or sulfonylureas

There are also considerations around anaesthesia, because slowed stomach emptying may increase the risk of inhaling stomach contents during sedation. If you are taking a GLP-1 medicine and need a procedure, tell the team in advance. See GLP-1 surgery and anaesthesia.

GLP-1 medicines also cause loss of some lean (muscle) mass along with fat, as does any substantial weight loss. Our guide to preserving muscle on GLP-1s covers this.

Risks of bariatric surgery

All surgery carries risk. Bariatric operations are now usually performed by keyhole (laparoscopic) surgery in specialist centres, and serious complications are uncommon, but they can include:

• bleeding, infection and blood clots in the legs or lungs
• leaks from staple lines or joins in the bowel
• narrowing (strictures) or ulcers at the join
• a small risk of death, which is low but not zero

Longer term, surgery can lead to:

• nutritional deficiencies, particularly of iron, vitamin B12, folate, calcium, vitamin D and protein, which is why lifelong supplements and blood tests are needed
• dumping syndrome after bypass, where sugary foods pass too quickly into the intestine, causing faintness, sweating and diarrhoea
• acid reflux, which can be new or worsened after sleeve gastrectomy
• gallstones during rapid weight loss
• changes in how alcohol is absorbed, raising the risk of alcohol-related harm
• psychological adjustment, including changes in body image and relationships with food

The NHS weight loss surgery pages give an overview of these risks, and a surgical team will discuss them individually.

Eligibility in the UK

NHS criteria for surgery

NICE guideline NG246 (which replaced the earlier obesity guideline CG189) sets out when bariatric surgery should be considered. In summary, surgery may be considered for people who:

• have a BMI of 40 kg/m² or more, or a BMI of 35 to 39.9 kg/m² with a significant health condition that could improve with weight loss (such as type 2 diabetes or high blood pressure)
• have been receiving, or will receive, care in a specialist weight management service
• are fit for anaesthesia and surgery
• commit to long-term follow-up

NICE also recommends an expedited assessment for surgery for people with recent-onset type 2 diabetes (diagnosed within the past ten years) who have a BMI of 35 or more, and that it should be considered for those with a BMI of 30 to 34.9. For people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background, these BMI thresholds are reduced by 2.5 kg/m². Our guide to BMI thresholds and ethnicity explains why.

In practice, NHS access to surgery is limited by capacity, and waiting lists in many areas are long.

Criteria for GLP-1 medicines

The licences for Mounjaro and Wegovy cover adults with a BMI of 30 or more, or 27 to 30 with at least one weight-related condition. NHS eligibility is narrower. NICE TA875 recommends Wegovy within specialist weight management services, and NICE TA1026 recommends Mounjaro for adults with a BMI of at least 35 and at least one weight-related condition, with NHS England phasing access in priority groups starting in June 2025. Private providers prescribe within the licence after their own clinical assessment. See who can get weight loss injections and Mounjaro on the NHS.

Many people who qualify for surgery also qualify for medication, so the decision often comes down to personal factors.

What might make one option more suitable

Every case is different, but these are some of the factors a specialist team might discuss.

Factors that may favour considering surgery

• a very high BMI, where the larger average weight loss from surgery may matter more
• type 2 diabetes where substantial, durable improvement is a priority
• a preference for a one-off intervention rather than open-ended medication
• previous GLP-1 treatment that was not tolerated or produced little effect
• concerns about long-term medication supply or cost

Factors that may favour considering medication

• higher surgical risk, for example due to other health conditions
• a preference to avoid an operation or permanent anatomical change
• a BMI below surgical thresholds
• a wish to see how much weight can be lost before deciding about surgery
• the ability to access and continue treatment long term

Combined and sequential approaches

The two are increasingly seen as complementary rather than competing:

• Before surgery: some teams use medication to reduce weight before an operation, which can make surgery technically easier and safer, although this is decided case by case.
• After surgery: GLP-1 medicines are sometimes used when weight is regained, or when weight loss after surgery is less than hoped. Evidence comes mostly from observational studies, and prescribing needs to take account of altered anatomy and nutrition.

What day-to-day life looks like with each

Starting GLP-1 treatment

Starting a GLP-1 medicine does not involve time off work or a hospital stay. After an assessment, which may be in person, by video or through an online questionnaire with identity and weight checks, you usually begin on a low starter dose. The dose is increased gradually, typically every four weeks for weekly injections, to limit side effects. Many people notice a reduced appetite within the first few weeks, while weight loss tends to build steadily over months.

Day to day, you will need to inject (or take a tablet) on schedule, store pens correctly, manage any side effects and attend reviews. Eating smaller portions, prioritising protein, drinking enough fluid and staying active help with both side effects and the quality of weight loss. Our guides on what to eat on a GLP-1 and exercise on a GLP-1 cover practical steps.

Recovering from bariatric surgery

Bariatric surgery usually involves a hospital stay of one to a few days, followed by several weeks of recovery before returning to work, depending on the job. Before the operation, many teams ask patients to follow a low-calorie liquid diet for a couple of weeks to shrink the liver, which makes keyhole surgery safer.

After surgery, eating is reintroduced in stages: liquids first, then puréed food, then soft food, and finally normal-textured food, over roughly six to eight weeks. Portions are much smaller than before, food must be chewed thoroughly, and drinking is usually separated from meals. Lifelong vitamin and mineral supplements are needed, and blood tests are recommended at least yearly. Specialist dietitians and psychologists are part of good surgical care.

Psychological aspects

Both treatments can change how people relate to food, and both can bring emotional adjustments as weight and appearance change. Some people find the quieting of constant food thoughts on GLP-1 medicines a relief; others find the change in appetite unsettling. After surgery, people sometimes struggle with the loss of food as a source of comfort. A history of eating disorders needs careful assessment before either treatment. Our guide to GLP-1s and mental health covers this in more depth.

Long-term commitment and cost

Both options are long-term commitments, in different ways.

With GLP-1 medicines, the evidence suggests most people need to keep taking them to maintain weight loss. In the STEP 1 extension, people regained around two-thirds of their lost weight within a year of stopping semaglutide. In SURMOUNT-4, people switched to placebo after 36 weeks of tirzepatide regained a substantial part of their lost weight, whereas those who continued lost more. Our guides to long-term GLP-1 use and weight regain after stopping look at this in depth.

With surgery, the commitment is to permanent dietary change, lifelong supplements, regular blood tests and follow-up.

Financially, private surgery involves a large one-off cost plus aftercare, whereas private medication involves an ongoing monthly cost for as long as it continues. We do not quote prices, but our guide to the long-term cost of GLP-1 treatment explains how to think about cumulative costs, and private vs NHS weight loss treatment compares the routes. If you are considering private medication, you can compare regulated providers on our providers page and see what affects cost on our prices page.

Questions to ask your GP or specialist team

• Based on my BMI and health, am I eligible for surgery, medication or both on the NHS?
• What is the likely benefit of each option for my specific conditions?
• What are the risks for me personally, given my medical history?
• How long is the local waiting list for a specialist weight management service or surgery?
• If I start medication, how long would I be expected to take it, and what happens if I stop?
• If I have surgery, what aftercare and supplements would I need for life?
• Could medication be used before or after surgery in my case?

When to speak to a professional

If you are thinking about either treatment, start with your GP. They can check your BMI and health, discuss NHS options and refer you to a specialist weight management service. Never start, stop or change a weight loss medicine without talking to your prescriber, and tell any surgical team about all medicines you take, including GLP-1s.

Seek urgent medical help (NHS 111, or 999 in an emergency) if you have:

• severe, persistent abdominal pain, with or without vomiting, especially if it spreads to your back (possible pancreatitis or, after surgery, a leak or obstruction)
• fever, rapid heart rate or feeling very unwell in the days or weeks after bariatric surgery
• pain in the upper right abdomen, fever, or yellowing of the skin or eyes (possible gallbladder problems)
• persistent vomiting, inability to keep fluids down or signs of dehydration
• vomiting blood, or black, tarry stools
• chest pain, breathlessness or a swollen, painful leg (possible blood clot)

If you have had bariatric surgery, contact your surgical team or GP about symptoms such as tingling, numbness, unusual tiredness or hair loss, which may suggest a nutritional deficiency.